MNK as a potential pharmacological target for suppressing LPS-induced acute lung injury in mice
Authors:
- 1 April 2021
- journal article
- research article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 186, 114499
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China
This publication has 41 references indexed in Scilit:
- Innate immune receptor Toll-like receptor 4 signalling in neuropsychiatric diseasesNeuroscience & Biobehavioral Reviews, 2016
- Acute Lung Injury: A Clinical and Molecular ReviewArchives of Pathology & Laboratory Medicine, 2016
- Identification of a Highly Conserved Allosteric Binding Site on Mnk1 and Mnk2Molecular Pharmacology, 2015
- MAP Kinase-Interacting Kinases—Emerging Targets against CancerChemistry & Biology, 2014
- MNK1 pathway activity maintains protein synthesis in rapalog-treated gliomasJournal of Clinical Investigation, 2014
- Mnk kinase pathway: Cellular functions and biological outcomesWorld Journal of Biological Chemistry, 2014
- Mnk1 and 2 Are Dispensable for T Cell Development and Activation but Important for the Pathogenesis of Experimental Autoimmune EncephalomyelitisThe Journal of Immunology, 2013
- An Official American Thoracic Society Workshop Report: Features and Measurements of Experimental Acute Lung Injury in AnimalsAmerican Journal of Respiratory Cell and Molecular Biology, 2011
- Therapeutic Inhibition of MAP Kinase Interacting Kinase Blocks Eukaryotic Initiation Factor 4E Phosphorylation and Suppresses Outgrowth of Experimental Lung MetastasesCancer Research, 2011
- The Mnks: MAP kinase-interacting kinases (MAP kinase signal-integrating kinases)Frontiers in Bioscience-Landmark, 2008